Falah and Rabee

Iraqi Journal of Science, 2022, Vol. 63, No. 10, pp: 4195-4204 DOI: 10.24996/ijs.2022.63.10.6





ISSN: 0067-2904

The Effects of Combined toxicity of Silver and Silicon Nanoparticles on Hematological and Biochemical Parameters in Male Albino Mice

Zahraa Falah*, Idan, Adel M. Rabee

Department of Biology, College of Science, University of Baghdad, Baghdad, Iraq

Received: 7/11/2021 Accepted: 18/1/2022 Published: 30/10/2022

Abstract

In this study, the potential combined effects of silver (AgNPs) and silicon dioxide nanoparticles (SiO₂NPs) on male albino mice which were exposed intraperitoneally to the 50 mg/kg and 100 mg/kg and mixed concentrations of nanoparticles (NPs) for periods of 2 and 4 weeks, were evaluated. The evaluation was performed by examining the haematological and biochemical parameters, in addition to the bioaccumulation of NPs in the liver and kidney. The results showed that the platelets count significantly increased in all exposed groups, while red blood cell count (RBCs) decreased in most exposed groups. White blood cells (WBCs) and haemoglobin (Hb) showed different levels in the exposed groups. Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) levels also showed a significant increase in the exposed groups, except in the groups exposed to 100 mg/kg of NPs for 2 weeks. Whereas blood urea nitrogen (BUN) serum level showed a significant decrease in all exposed groups. However, the alkaline phosphatase (ALP), uric acid (UA) and creatinine (CR) levels did not show any significant alternations in the exposed groups. Significant increase was also noted in thyroid-stimulating hormone (TSH) levels among the exposed groups. An accumulation of AgNPs and SiO₂NPs was observed both in livers and kidneys in the exposed groups. The results showed that SiO₂NPs have a synergistic effect on AgNPs accumulation in the groups exposed to mixed nanoparticles.

Keywords: Bioaccumulation, AgNPs, SiO2NPs, Creatinine, RBCs, AST

التأثيرات السميةالمشتركة لدقائق الفضةوالسيلكون النانوية على المؤشرات الدموية والكيمياوية لذكور الفئران البيضاء

زهراء فلاح عيدان *، عادل مشعان ربيع قسم علوم الحياة، كلية العلوم، جامعة بغداد،بغداد، العراق

الخلاصة

تم تقييم التأثير المشترك المحتمل لدقائق الفضة النانوية (AgNPs) ودقائق ثاني أكسيد السيليكون النانوية (SiO₂NPs) على ذكور الفئران البيضاء،والتي تم تعريضها إلى التركيز 100 ملغرام/ كغم و50ملغرام / كغم والمختلط من الجسيمات النانوية لمدة 2 و4 أسابيع. تم إجراء التقييم من خلال فحص مؤشرات الدم المؤشرات الكيموحيوية والتراكم الحيوي للدقائق النانوية في الكبد والكلى. اظهرت النتائج زيادة ملحوظه في عدد الصفائح

^{*}Email: <u>zahraa96zz33@gmail.com</u>

الدموية في جميع المجموعات المعرضة، بينما انخفض عدد خلايا الدم الحمراء (RBC) في معظم المجموعات المعرضة. أظهرت خلايا الدم البيضاء (WBCs) والهيموكلوبين (Hb) مستويات مختلفة في المجموعات المعرضة. أظهرت مستويات ناقلة أمين الأسبارتات (AST) و ناقل أمين الألنين (ALT) زيادة معنوية في المجموعات المعرضة، باستثناء المجموعات التي تعرضت لـ 100 مجم / كجم من الدقائق النانوية لمدة أسبوعين. بينما أظهر نيتروجين اليوريا في الدم (BUN) انخفاضًا معنويًا في جميع المجموعات المعرضة. ومع ذلك، فإن مستويات الفوسفتيز القلوي (ALA)، حامض اليوريك (UA) ومستويات الكرياتينين (RS) لم تظهر تغيرا كبيرًا في المجموعات المعرضة. فضلا عن ذلك لوحظت زيادة كبيرة في مستويات هرمون الغدة الدرقية (TSH) في المجموعات المعرضة. وتم ملاحظة تراكم دقائق الفضة النانوية ودقائق ثاني أكسيد السيليكون النانوية في كل من الكبد والكلى في المجموعات المعرضة. تظهر النائية أن يأكسيد السيليكون النانوية في كل من الكبد والكلى في المجموعات المعرضة. تظهر النائوية مانوي أني أكسيد في المجموعات المعرضة الدقائق الفضة النانوية مانوية في مستويات هرمون الغدة الميليكون النانوية في كل من الكبد والكلى في المجموعات المعرضة. المعرضة. الموضة النانوية مانوي أني أكسيد في المجموعات المعرضة الدقائق الفضة النانوية ودقائق ثاني أكسيد

1. Introduction

The nanotechnology revolution has brought benefits into almost every aspect of life. Several products contain nanoparticles (NPs) in their basic structure, for that the possibility of exposure to nanoparticles (NPs) and nanomaterials (NMs) is high, particularly during product series manufacture, application and waste disposal [1]. However, NMs are defined as materials consisting of nanoparticles that have at least one or more external dimensions between 1 and 100 nanometers [2].NPs enter the body of living organisms through various routes of exposure involving inhalation, ingestion, dermal contact and systematic exposure [3]. The physicochemical properties including size, surface charge, shape, surface area, surface modification, stability and density have a great influence on the absorption, distribution, metabolism and excretion (ADME) of NPs [4, 5]. Owing to their unique characteristics, silver nanoparticles (AgNPs) and silicon dioxide nanoparticles (SiO₂NP) are among the most commonly used and manufactured engineered nanomaterials (ENMs) [6]. Besides their application in the environment, they are applied in various fields including industrial, agriculture, medical, nutrition, healthcare and consumer applications [7, 8]. Until 2012 about 1.5 million tons of SiO2NPs were released in the global market, leading to SiO₂NPs becoming among the most produced nanoparticles in 2013 [9, 10]. The evaluated worldwide production volume of AgNPs was approximately 500 tons per year [11]. With the wide use of NMs, the necessity to understand their adverse effects on public health and the environment has also increased which has led to the emergence a new field called nanotoxicology. It is a study of the toxic effects of NMs interactions with biological systems [12]. For example, some studies found out that an interaction with blood components (plasma proteins, coagulation factors, RBCs, WBCs and platelets) is believed to occur whenever NPs reach the systemic circulation [13]. Moreover, the in vivo and in vitro studies have demonstrated that exposure to AgNPs not only causes alternation in the blood and biochemical indicators, but also organs inflammations [14, 15]. It was also demonstrated that the toxic effects occur when reactive oxygen species (ROS) levels rise, resulting in oxidative stress damage [16, 17]. Furthermore, the accumulation of AgNPs and SiO₂NPs was observed in the liver, kidney, spleen, lungs and brain of rats [18, 19]. Widespread application of the various types of nanoparticles brings the risk of co-exposure. However, once the combination of nanoparticles enters the organisms bodies, it undergoes different physicochemical interactions which may result in changes in their prime characteristics and affect their bioavailability as a consequence. It also affects their toxicity which could become either less or more toxic [20].

2. Methods and Materials

2.1. Nanoparticles

The studied AgNPs were dark gray nano-powder (20-30 nm) particles spherical in shape and had 99.95% purity with a density of 10.5 g/cm³. While SiO₂NPs were in white nanopowder form (20-23 nm) with 95.9% purity and a density of 2.4 g./cm 3. These nanoparticles powders were obtained from Areej Al-Furat Company (a chemicals Company in Baghdad, Iraq)

2.2. Animal Housing

Albino male mice (*Mus musculus*), with an average body weight of 30 ± 5 g, were used in the current study. The animals were housed in polypropylene cages in a specially controlled environment with 12 on 12 hours of light and darkness. Temperature was kept at 25°C with a relative humidity of 50-60%. The nutrition sources were available 24 hours a day. The animals were cared for and housed in the animal house at the Biotechnology Research Center, Al Nahreen University.

2.3. Preparation of nanoparticles suspension

The suspension of the NPs was prepared by suspending weighed AgNPs and SiO_2NPs with deionized distilled water and putting the suspension tube in an ultrasonic bath for 60 minutes by using Branson 3510 (Memmert\Germany). The suspension of MiXNPs was prepared by mixing AgNPs and SiO₂NP suspensions.

2.4. Subchronic toxicity test of AgNPs, SiO2NPs, and MiXNPs

Mice were divided into eight groups (each group with 10 animals) and injected intraperitoneally three times a week with two different concentrations (50 and 100 mg/kg) of AgNPs, SiO₂NPs and MiXNPs for 2 and 4 weeks.

2.4.1. Hematological parameters

In order to examine hematological parameters, three animals were taken from each group including the control group. The blood samples, taken by heart puncture at the end of 2^{nd} and 4^{th} week, were then put in ethylenediaminetetraacetic acid (EDTA) tubes. Later complete blood counts (CBC) including red blood cell counts (RBC), white blood cell counts (WBC), hemoglobin (Hb) and platelets (PLTs) were immediately assessed using a fully automated digital hematology analyzer.

2.4.2. Biochemical parameters

The serum alkaline phosphatase activity (ALP), serum alanine aminotransferase activity (ALT) and serum aspartate aminotransferase activity (AST) were also measured, in addition to serum level of blood urea nitrogen (BUN), creatinine (CR) and uric acid (UA). The samples were collected from three members of each group, then placed in a gel tube, were later examined by using an A 15 analyzer (Biosystems/Spain). Thyroid Stimulating Hormone (TSH) was examined by an AFIAS-6 analyzer (Boditech/South Korea). The assessment was performed using specific kits and quality control reagents for validation.

2.4.3. Bioaccumulation study

About 0.25-0.5 g of organ tissues (liver and kidney) was weighed. Samples were prepared by using a microwave digestion system method [21].Concentration assays were performed by using an atomic absorption flame emission spectrophotometer (Perkin Elmer/ USA) for detecting the AgNPs. UV-visible spectrophotometer (Analytic Jena/Germany) was used to detect SiO₂NPs.

2.5. Statistical analysis

Statistical Analysis System- SAS (2012) program was used to detect the effects of various factors in study parameters. In this study, the least significant difference (LSD) test in the context of the analysis of Variance(ANOVA) was used to compare means.

3. Results and Discussion

3.1 Subchronic toxicity

3.3.1. Hematological parameters

Hematological parameters are used to determine the physiological response to an introduced substance. The changes in hematological parameters of the exposed mice are shown in Table 1.

A significant decrease in RBC counts was noticed in all AgNPs treated groups. \L) After exposure to 50 mg/kg for 4 weeks, the lowest mean value recorded was $5.16 \pm 2.50 \ 10^{12}$ \L. While non-significant decrease values were noted in the groups treated with SiO₂NPs, except in the groups exposed to 50 mg/kg for 4 weeks which recorded a significant increase. A significant decrease in RBC count was noted in groups treated with 100 mg/kg of MiXNPs, compared to the control group. The toxicity studies reported toxic effects of nanoparticles on RBCs which could be related to the large surface area of NPs compared to its size. Nanoparticles have the potential to cause hemolysis due to their large surface area that could enable more ions to be released. Both ions released by nanoparticles and the direct interaction of nanoparticles with RBCs result in the production of oxidative stress (ROS), membrane injury, and subsequently hemolysis [22, 23]. A significant decrease in Hb values was indicated after 2 weeks of exposure to AgNPs. The lowest mean value recorded was 10.86 ±1.18 after being exposed to 100 mg/kg of AgNPs for 2 weeks. Whereas, Hb values significantly increased in the groups treated with SiO₂NPs.The highest recorded value was 16.95 \pm 3.65 g/dL. Hb values also increased 14.70 \pm 2.46 g/dL after being exposed to 50 mg/kg of MiXNPs for 4 weeks, while the values decreased after 2 weeks of exposure to 100 mg/kg of MiXNPs; compared with the control group (12.72 ±0.75 g/dL). Non-significant changes in Hb value were noted in mice exposed to 100 mg/kg AgNPs, SiO₂NPs and MiXNPs for 4 weeks. The changes in RBCs and hemoglobin (Hb) levels may suggest that NPs are affecting their synthesis in the time of RBCs maturation and the production in the bone marrow [24]. Significant changes were indicated in WBCs counts after being exposed to AgNPs with the highest mean value of 8.96 \pm 1.13 10⁹/L after being exposed to 50 mg/kg of AgNPs for 4 weeks. The WBCs counts significantly increased in groups treated with SiO₂NPs with the highest count of 14.40 $\pm 2.10 \ 10^9$ \L observed after being exposed to 50 mg/kg for 2 weeks\). Furthermore, WBCs count significantly increased in groups exposed to MiXNPs for 2 weeks, while it significantly decreased in the groups exposed to MiXNPs for 4 weeks; compared with the control group. The increase in WBCs count indicates an increase in immunogenic response [15, 16]. This decrease in the number of WBCs could possibly be because most particles accumulated in the organ tissues or were removed from the body by the liver and kidneys, resulting in a lower number of particles remaining in the blood [15]. The PLTs counts significantly increased in all treated groups, with different concentrations of NPs at all times of exposure, compared to the control group. This increase in PLTs number indicates anemia or other inflammatory diseases. High level of PLTs could lead to the formation of thrombus in the blood vessels which can promote the progression of atherosclerosis [25].

Table 1: Mean±standard of a hematological parameters of albino mice after 2 and 4 weeks of exposed intraperitoneally to 50 and 100 mg\kg concentrations of AgNPs, SiO2NP and MiXNPs.

Period AgNPs	Parameters	100 n	ng\kg	50 mg	¦∖kg	LSD Value
2 WEEKS	WBC 10 ⁹ \L	6.61 ±2.54 a	6.13 ±1.65 ab	5.90 ±0.50 b	6.13 ±1.65 ab	0.662 *
	$RBC \ 10^{12} \text{L}$	7.53 ±0.77 b	8.10 ±.24 a	$6.06 \pm 0.05 c$	8.10 ±0.24 a	0.847 *
	Hb g\dl	10.86 ±1.18 b	12.72 ±0.75a	12.35 ±0.25 a	12.75±0.75a	1.33 *
	PLT 10 ⁹ \L	926.67±173.2 7 a	224.87±107.7 5 b	955.50 ±42.50 a	224.87±107.7 5 b	174.38 *
EKS	WBC 10°\L	6.29 ±3.31 c	7.82 ±1.67 b	8.96 ±1.13 a	7.82 ±1.67 b	0.807 *
	RBC 10 ¹² \L	7.20 ±0.05 b	7.80 ±0.49 b	5.16 ±2.50 b	7.80 ±0.49 a	0.936 *
WE	Hb (g\DI)	12.25 ±0.05 b	12.00± 0.30 b	14.30 ± 0.75 a	12.00 ±0.30 b	1.735 *
4	PLT 10 ⁹ \L	833.50±84.50 a	426.25±108.9 5 b	1227.00±345.50 c	426.25±108.9 5 b	308.51 *
Period	Parameters	100 n	ng\kg	50 mg	LSD Volue	
SiO2NP s						value
	WBC 10 ⁹ \L	9.16 ±0.11 b	6.13 ±1.65 c	14.40 ±2.10 a	6.13 ±1.65 c	2.372 *
2 WEEKS	RBC 10^{12} \L	7.28 ± 0.91	8.10 ±.24	7.91 ±0.46	8.10 ±.24	0.894 NS
	Hb g\dL	10.15 ± 0.95	12.72 ± 0.75	16.95 ± 3.65	12.72 ± 0.75	2.375 *
	PLT 10 ⁹ \L	1521.50±202. 50 a	224.87±107.7 5 c	1027.00 ±139.00 b	224.87±107.7 5 c	261.48 *
EKS	WBC 10 ⁹ \L	7.04 ±2.25 c	7.82 ±1.67 b	8.86 ±1.16 a	7.82 ±1.67 b	0.794 *
	$RBC \ 10^{12} L$	7.50 ±0.14 a	7.80 ±0.49 a	8.37 ±1.23 b	7.80 ±0.49 b	0.885 NS
ME	Hb g\dL	12.26 ±0.91 b	12.00 ±0.30 b	15.80 ±1.80 a	12.00 ±0.30 b	2.074 *
4	PLT 10 ⁹ \L	836.33 ±86.41	426.25±108.9	1034.67 ±181.96	426.25±108.9	277.612
Period	Parameter	a 100 n	ng\kg	a 50 50 mg\kg		·
MiXNPs	-		0.0	c		LSD Value
	WBC10 ⁹ \L	7.72 ±0.93 a	6.13 ±1.65 b	7.15 ±1.35 a	6.13 ±1.65 b	0.709 *
2 WEEKS	RBC10 ¹² \L	7.62 ±0.57 ab	8.10 ±.24 a	6.74 ±0.34 b	8.10 ±0.24 a	1.026 *
	Hbg\dL	10.90 ±0.66 b	12.72 ±0.75 a	12.75 ±1.65 a	12.72 ±0.75 a	1.69 *
	PLT10 ⁹ \L	1056.33±132. 51 a	224.87±107.7 5 b	1273.50 ±332.50 a	224.87±107.7 5 b	286.94 *
	WBC10 ⁹ \L	6.36 ±1.59 b	7.82 ±1.67 a	6.90 ±1.39 b	7.82 ±1.67 a	0.779 *
EK	$RBC \ 10^{12} \text{L}$	$7.70\pm\!\!0.36$	7.80 ± 0.49	7.61 ± 0.89	7.80 ± 0.49	0.569 NS
WE	Hbg\dL	11.26 ±0.77 b	12.00 ±0.30 b	14.70 ±2.46 a	12.00 ±0.30 b	2.066 *
4	PLT10 ⁹ \L	634.33±104.2 1 ab	426.25±108.9 5 b	978.67 ±445.33 a	426.25±108.9 5 b	269.03 *
M	eans having wit	th the different le	etters in the same	e row differed signi	ficantly. * (P≤0.0	5).

3.3.2. Biochemical parameters

The biochemical parameters such as serum enzymes are used (as biomarkers) to indicate the toxic effects that organisms could be exposed to from environment pollution including NPs. Changes in biochemical parameters of exposed mice are shown in Table 2.

The mean value of ALT, ALP and AST levels showed non-significant changes after mice groups were treated with 100 mg/kg of AgNPs, SiO₂NPs, and MiXNPs for 2 weeks. While the ALT, ALP and AST levels significantly changed after 4 weeks of exposure to 100 mg\kg of studied NPs, except in the group treated with AgNPs where the ALP level showed nonsignificant change. However, after mice groups were treated with 50 mg/kg of AgNPs, SiO2 NPs, and MiXNPs, ALT and AST levels significantly increased in both time exposures (2 and 4 weeks). The noted highest mean value was 47.00 ± 0.5 U/L (in mice group treated with 50 mg\kg of SiO₂NPs), and 144.67 ±0.88 U/L (in mice group treated with 50 mg/kg of MiXNPs) respectively. Whereas ALP level showed no change; compared to the control group. High level of AST indicates liver diseases [26]. A low level of AST is likely to occur with either liver or kidney disease, and/or inflammatory diseases [27]. ALT increase mostly indicates liver cells damage. However, ALT release is associated with liver tissue injury [28]. The abnormalities in ALP levels may be an indication of various diseases including hepatitis, gallstones and thyroid disease [29, 30]. However, the histopathological examination of the liver shows various alterations that indicate hepatotoxic effects of AgNPs, including hepatocellular degeneration [31]. The mean value of BUN levels significantly decreased in all treated groups with studied NPs for 2 and 4 weeks, except the group treated with MiXNPs for 4 weeks where no significant change in BUN level was noted. The lowest recorded value was 22.33 ±2.88 mg/dl. The mean value of UA level showed a non-significant change in the treated groups except the group treated with 50 mg/kg of MiXNPs for 2 weeks which observed significant changes with the recorded lowest value of 1.80 ±0.50 mg/dl. The CR level showed a significant decrease after mice were treated with 50 of SiO₂NPs for 2 weeks and 50 mg/kg of MiXNPs for 4 weeks where the observed lowest level was 0.133 ±0.03 mg/dl. While the CR level increased significantly after 2 weeks of MiXNPs exposure, since urea, uric acid and creatinine are waste products produced by the liver and removed by the kidney [32]. The BUN, UA and CR levels are considered as indicators of kidney and liver functions where high levels of BUN and CR indicate kidney disease or organ failure, while the low levels may indicate liver diseases. The histological examination demonstrated adverse effects of NPs in the kidney, for example tissue necrosis of glomerular cells and damage in the epithelium layer of the Henley loop were observed after AgNPs exposure [31]. Also pathological change in the kidney tissues was noted after the exposure to SiO2NPs [33]. Regarding TSH levels, the result showed a significant increase of 0.300 $\pm 0.00 \mu$ U/ml in the group treated with 50 mg/kg of AgNPs for 4 weeks. Significant increase of 0.250 ±0.05 μ U/ml was also noted in the treated groups with 100 mg/kg of SiO₂NPs for 2 weeks. Significant increase in TSH levels was also noted in the groups treated with 100 mg/kg for 2 weeks and 50 mg/kg for 4 weeks of MiXNPs. However, a significant decrease was observed in the groups treated with 100 mg\kg MiXNPs for 4 weeks; compared with the control group. The change in hormone concentrations could be attributed to increased oxidative stress caused by NPs, which results in ROS and altered hormone levels. Besides NPs have an ability to penetrate tissues which causes inflammation or structural and functional disorders of the thyroid gland that is reflected on thyroid hormone (TSH) secretion [34].

Table 2: Mean ±standard of a biochemical parameters of albino mice after 2 and 4 weeks of exposed intraperitoneally to 50 and 100 mg\kg concentrations of AgNPs, SiO2NP and MiXNPs.

Period (Weeks)\ Concentration(m	Groups	Parameters						
g\kg)		ALT U/L	ALP U/L	AST U/L	BUN mg/dl	CR mg/dl	UA mg/dl	TSH μU/ml
2\100	AgNPs	45.33	93.00	146.00	27.67	0.200	2.40	0.133
	-	±0.88 a	±0.57 a	±1.15 a	±0.88 a	±0.05 a	±0.11 a	±0.03 a
	SiO2N	46.00	92.00	145.50	26.50	0.250	2.20	0.250
	PS	±3.00 a	±1.00 a	±2.50 a	±0.50 a	±0.05 a	±0.20 a	±0.05 b
	MiXN	48.33	94.00	148.00	26.33	0.200	2.33±0.	0.233±0.
	Ps	±1.20 a	±0.57 a	±2.00 a	±1.76 a	±0.06 a	23 a	03 c
	Contro	46.88	96.05	142.66	32.38	0.315	2.40	0.150
	1	±6.71 a	±2.05 a	±7.33 a	±3.11 b	±0.02 a	±0.20 a	±0.05 a
	LSD	10.052N	3.461	11.24 NS	5.996 *	0.196	0.686	0.139
		S	NS			NS	NS	NS
4\100	AgNPs	45.00	89.33	134.53	22.33	0.263	2.36	0.150
	~~~	±2.51 a	±2.40 a	±5.75 a	±2.88 a	±0.02 a	±0.12 a	±0.03 a
	SiO2N	44.53	89.33	194.67	22.73	0.220	2.33	0.150
	PS	$\pm 2.82$ a	±1.45 a	±22.84 b	±2.18 a	±0.01 b	$\pm 0.08$ a	$\pm 0.02$ a
	MIXN	44.16	89.00	189.33	25.26	0.233	2.26	0.100
	PS Control	±2.09 a	$\pm 1.15$ a	±19.67 b	$\pm 1.88$ a	$\pm 0.02$ a	$\pm 0.08$ a	±0.00 b
	Contro	54.30	100.96	157.40	39.80	0.286	2.07	0.16/
	I	±0.04 0	$\pm 1.920$	±2.92 C	$\pm 0.03$ U	$\pm 0.02$ a	$\pm 0.00 a$	$\pm 0.05 a$
	LSD	7.12 **	5.800 *	50.28 *	15.894 *	0.0595 *	0.302 NS	0.085 NS
2\50	AgNPs	44.33	93.67	139.00	29.33	0.333	2.16	0.233
		±2.84 a	±1.20 a	±2.64 a	±1.45 a	±0.08 a	±0.13 a	±0.06 a
	SiO2N	47.00±0.	92.00±1.	143.00	22.52±1.	0.133±0.	2.06	0.233
	PS	57 a	52 a	±3.21 b	38 b	03 b	±0.23 a	±0.08 a
	MiXN	47.00	92.33	144.00	24.96	0.600	1.80	0.200
	Ps	$\pm 3.60$ a	±0.88 a	±3.60 b	±2.78 b	±0.23 c	±0.50 b	±0.05 a
	Contro	21.80	94.00	50.13±21.	29.07	0.320	3.10	0.205
		±8.20 b	$\pm 1.00$ a	40 C	$\pm 0.2/a$	$\pm 0.02$ a	±0.20 a	$\pm 0.01$ a
	LSD	12.55 *	4.192INS	25.71 *	0.515 *	0.473 NS	1.105 *	0.236 NS
4\50	AgNPs	46.50	92.50	144.50	26.00	0.300	2.65	0.300
		±0.50 a	±2.50 a	±4.50 a	±4.00 a	±0.00 a	±0.05 a	±0.00 a
	SiO2N	46.33	93.33	143.67	27.67	0.300	2.33	0.166
	PS	±1.76 a	±0.67 a	±3.28 a	±1.45 b	±0.06 a	±0.17 a	±0.06 b
	MiXN	45.66	95.33	144.67	28.66	0.133	2.30	0.266
	Ps	±2.18 a	±0.88 a	±0.88 a	±1.45 b	±0.03 b	±0.34 a	±0.03 c
	Contro	31.81	99.57	84.85	29.62	0.283	2.73	0.203
		±11.80 b	$\pm 3.75 a$	±36./1 b	$\pm 0.52 \text{ b}$	±0.04 a	$\pm 0.14$ a	±0.01 b
	LSD	23.011 *	7.882NS	55.085 *	5.943NS	0.151 *	0.788 NS	0.141 NS
Means having with	the differe	ent letters i	n the same i	row differed	significant	ly (P≤0.05)		

## 3.3.3. Bioaccumulation study

In order to determine, the accumulation of studied NPs (AgNPs, SiO2 NPs, and MiXNPs), the deposition of NPs in the organs of treated animals (liver and kidney) were measured as shown in Table 3.

An accumulation was observed in the livers and kidneys of the treated group with 100 mg/kg of AgNPs (G1). While in the group treated with 100 mg/kg of  $SiO_2NPs$  (G2), the accumulation was noted only in the kidneys, compared with the control group. However, the

group exposed to 100 mg/kg of MiXNPs showed more accumulation of AgNPs compared with G1 and the control, and SiO₂NPs showed a different ratio of accumulation compared with G2 and the control group. At 50 mg/kg dose, the group treated with AgNPs showed an accumulation in both livers and kidneys, while accumulation of SiO₂NPs was noted only in the kidneys, compared with the control group. However, the accumulation of AgNPs and SiO₂NPs was noted in the group treated with 50 mg/kg of MiXNPs. After the exposure to nanoparticles and blood circulation, the distribution in many organs including the liver, spleen and kidneys occurs. "Dziendzikowska" [35] suggested that the liver is the first line of defense against NPs, for that the deposition of the non-biodegradable nanoparticles are likely to occur. Although the amount of these particles is translocated to other organs like the kidney and spleen [36, 37]. An accumulation of AgNPs after intraperitoneal exposure in body organs mostly the liver and kidneys, were observed by Razooki [38]. A previous study showed that SiO₂NPs could accumulate in the liver [20]. Furthermore, many researchers indicated that SiO₂NPs can be accumulated in kidney tissue [31, 39].

**Table 3**: The bioaccumulation in liver and kidney of albino mice after 4 weeks of exposed intraperitoneally to 50 and 100 mg/kg concentrations of AgNPs, SiO2NP and MiXNPs.

L	2	010	U,			
Concentration	Organs	AgNPs	SiO2NPs	MiXNPs		
		(G1)	(G2)	AgNPs	SiO2NPs	
100 mg/kg	Liver	1.7 ppm	17 ppm	2.94 ppm	22 ppm	
100 mg\kg	Kidney	1.9 ppm	23.5 ppm	2.37 ppm	19.5 ppm	
Concentration	Organs	A aNDa	SiO2NDs	MiXNPs		
Concentration		Agivis	5102141 5	AgNPs	SiO2NPs	
50 mg\ka	Liver	2.31 ppm	15	2.17 ppm	18.5 ppm	
50 mg/kg	Kidney	2.68 ppm	21 ppm	1.34 ppm	19 ppm	
Control	Liver	0.00	16.5ppm	0.00	16.5 ppm	
	Kidney	0.00	16.5ppm	0.00	16.5ppm	
Means having with the different letters in the same row differed significantly. * (P $\leq$ 0.05)						

## Conclusions

The current study concludes that the exposure to nanoparticles (AgNPs, SiO₂NPs, and MiXNPs) induced clear and significant changes in blood parameters in all treated groups. The biochemical parameters of liver and kidney showed more alternations after being exposed to 50 mg\kg of studied nanoparticles compared with 100 mg\kg. However, the effects were more visible after 4 weeks of exposure. ALT, AST, and BUN were the most affected parameters; compared with the control groups. The results suggest that the combination of AgNPs and SiO₂NPs has a synergetic effect on thyroid-stimulating hormone (TSH) levels. The bioaccumulation study showed the capability of the liver and kidney on accumulating the AgNPs and SiO₂NPs respectively. However, the combination of nanoparticles demonstrated a synergetic effect on AgNPs accumulation.

## References

- [1] N. Strambeanu, L. Demetrovici, D. Dragos and M. Lungu, "Nanoparticles: Definition, classification and general physical properties." In *Nanoparticles' promises and risks*, pp. 3-8. Springer, Cham, 2015
- [2] S. Sahoo, S. Parveen and J. Panda, "The present and future of nanotechnology in human health care", *Nanomedicine: Nanotechnology, Biology and Medicine*, vol. 3, no. 1, pp. 20-31, 2007.
- [3] M. Sajid, M. Ilyas, C. Basheer, M. Tariq, M. Daud, N. Baig, and F. Shehzad, "Impact of nanoparticles on human and environment: Review of toxicity factors, exposures, control strategies, and future prospects," *Environmental Science and Pollution Research*, vol. 22, no. 6, pp. 4122–4143, 2014.

- [4] F. Zhao, Y. Zhao, Y. Liu, X. Chang, C. Chen and Y. Zhao, "Cellular Uptake, Intracellular Trafficking, and Cytotoxicity of Nanomaterials", *Small*, vol. 7, no. 10, pp. 1322-1337, 2011.
- [5] S. M. M. Razooki and A. M. Rabee, "Evaluation of the Toxicological Effects of Zinc Oxide Nanoparticles in Albino Male Mice", *eijs*, vol. 61, no. 1, pp. 42-58, Jan. 2020.
- [6] B. KIM, H. KIM and I. YU, "Assessment of Nanoparticle Exposure in Nanosilica Handling Process: Including Characteristics of Nanoparticles Leaking from a Vacuum Cleaner", *Industrial Health*, vol. 52, no. 2, pp. 152-162, 2014.
- [7] H. Chang and S. Sun, "Silicon nanoparticles: Preparation, properties, and applications", *Chinese Physics B*, vol. 23, no. 8, p. 088102, 2014.
- [8] M. M. Ghobashy, M. A. Elkodous, S. H. Shabaka, S. A. Younis, D. M. Alshangiti, M. Madani, S. A. Al-Gahtany, W. F. Elkhatib, A. M. Noreddin, N. Nady, and G. S. El-Sayyad, "An overview of methods for production and detection of silver nanoparticles, with emphasis on their fate and toxicological effects on human, soil, and aquatic environment," *Nanotechnology Reviews*, vol. 10, no. 1, pp. 954–977, 2021.
- [9] C. Liljenström, D. Lazarevic and G. Finnveden, "Silicon-based nanomaterials in a life-cycle perspective, including a case study on self-cleaning coatings", 2013.
- [10] A. Syafiuddin, Salmiati, M. Salim, A. Beng Hong Kueh, T. Hadibarata and H. Nur, "A Review of Silver Nanoparticles: Research Trends, Global Consumption, Synthesis, Properties, and Future Challenges", *Journal of the Chinese Chemical Society*, vol. 64, no. 7, pp. 732-756, 2017.
- [11] G. Oberdörster, E. Oberdörster and J. Oberdörster, "Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles", *Environmental Health Perspectives*, vol. 113, no. 7, pp. 823-839, 2005.
- [12] OberdÃrster, "Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology", *Journal of Internal Medicine*, vol. 267, no. 1, pp. 89-105, 2010.
- [13] E.-J. Park, E. Bae, J. Yi, Y. Kim, K. Choi, S. H. Lee, J. Yoon, B. C. Lee, and K. Park, "Repeateddose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles," *Environmental Toxicology and Pharmacology*, vol. 30, no. 2, pp. 162–168, 2010.
- [14] S. Bronnikova and A. Stoinova, "The study of toxicity of silver and gold nanoparticles", *Terapevt* (General Physician), no. 1, pp. 66-68, 2021.
- [15] E. Park and K. Park, "Oxidative stress and pro-inflammatory responses induced by silica nanoparticles in vivo and in vitro", *Toxicology Letters*, vol. 184, no. 1, pp. 18-25, 2009.
- [16] R. Shrivastava, P. Kushwaha, Y. Bhutia and S. Flora, "Oxidative stress following exposure to silver and gold nanoparticles in mice", *Toxicology and Industrial Health*, vol. 32, no. 8, pp. 1391-1404, 2014.
- [17] A. Nemmar, S. Beegam, P. Yuvaraju, J. Yasin, A. Shahin and B. Ali, "Interaction of Amorphous Silica Nanoparticles with Erythrocytesin Vitro: Role of Oxidative Stress", *Cellular Physiology and Biochemistry*, vol. 34, no. 2, pp. 255-265, 2014.
- [18] L. Kramer, G. Winter, B. Baur, A. J. Kuntz, T. Kull, C. Solbach, A. J. Beer, and M. Lindén, "Quantitative and correlative biodistribution analysis of 89zr-labeled mesoporous silica nanoparticles intravenously injected into tumor-bearing mice," *Nanoscale*, vol. 9, no. 27, pp. 9743–9753, 2017.
- [19] Z. Ferdous and A. Nemmar, "Health Impact of Silver Nanoparticles: A Review of the Biodistribution and Toxicity Following Various Routes of Exposure", *International Journal of Molecular Sciences*, vol. 21, no. 7, p. 2375, 2020.
- [20] D. Wang, Y. Gao, Z. Lin, Z. Yao and W. Zhang, "The joint effects on Photobacterium phosphoreum of metal oxide nanoparticles and their most likely coexisting chemicals in the environment", *Aquatic Toxicology*, vol. 154, pp. 200-206, 2014.
- [21] D. Remeteiová, S. Ružičková, V. Mičková, M. Laubertová and R. Slezáková, "Evaluation of US EPA Method 3052 Microwave Acid Digestion for Quantification of Majority Metals in Waste Printed Circuit Boards", *Metals*, vol. 10, no. 11, p. 1511, 2020.
- [22] L. Chen, L. Fang, J. Ling, C. Ding, B. Kang and C. Huang, "Nanotoxicity of Silver Nanoparticles to Red Blood Cells: Size Dependent Adsorption, Uptake, and Hemolytic Activity", *Chemical Research in Toxicology*, vol. 28, no. 3, pp. 501-509, 2015.

- [23] S. Mukhopadhyay, H. Veroniaina, T. Chimombe, L. Han, W. Zhenghong and Q. Xiaole, "Synthesis and compatibility evaluation of versatile mesoporous silica nanoparticles with red blood cells: an overview", *RSC Advances*, vol. 9, no. 61, pp. 35566-35578, 2019.
- [24] A. AL-Baker, A. AlKshab and H. Ismail, "Effect of silver nanoparticles on some blood parameters in rats", *Iraqi Journal of Veterinary Sciences*, vol. 34, no. 2, pp. 389-395, 2020.
- [25] P. von Hundelshausen and C. Weber, "Platelets as Immune Cells", *Circulation Research*, vol. 100, no. 1, pp. 27-40, 2007.
- [26] M. Heydrnejad, R. Samani and S. Aghaeivanda, "Toxic Effects of Silver Nanoparticles on Liver and Some Hematological Parameters in Male and Female Mice (Mus musculus)", *Biological Trace Element Research*, vol. 165, no. 2, pp. 153-158, 2015.
- [27] L. Ray, R. Sarangi, A. Chatterjee, S. Ganguly and S. Nanda, "A comparative study of serum aminotransferases in chronic kidney disease with and without end-stage renal disease: Need for new reference ranges", *International Journal of Applied and Basic Medical Research*, vol. 5, no. 1, p. 31, 2015.
- [28] A. Baraaj, "Histological, Biochemical and DNA Changes in the Liver of Male Albino Rats Treated with Silver Nanoparticles", *Nano Biomedicine and Engineering*, vol. 13, no. 1, 2020.
- [29] D. Cooper, "Alkaline Phosphatase Isoenzyme Patterns in Hyperthyroidism", *Annals of Internal Medicine*, vol. 90, no. 2, p. 164, 1979.
- [30] O. Adeyemi and I. Adewumi, "Biochemical Evaluation of Silver Nanoparticles in Wistar Rats", *International Scholarly Research Notices*, vol. 2014, pp. 1-8, 2014.
- [**31**] T. Liu, L. Li, C. Fu, H. Liu, D. Chen and F. Tang, "Pathological mechanisms of liver injury caused by continuous intraperitoneal injection of silica nanoparticles", *Biomaterials*, vol. 33, no. 7, pp. 2399-2407, 2012.
- [**32**] J. Salazar, "Overview of Urea and Creatinine", *Laboratory Medicine*, vol. 45, no. 1, pp. e19-e20, 2014. Available: 10.1309/lm920sbnzpjrjgut.
- [33] R. Hussein and O. Sarhan, "Effects of intraperitoneally injected silver nanoparticles on histological structures and blood parameters in the albino rat", *International Journal of Nanomedicine*, p. 1505, 2014.
- [34] K. Hashem, K. M. Hassnin, and S. H. AbdEl-Kawi, "The prospective protective effect of selenium nanoparticles against chromium-induced oxidative and cellular damage in rat thyroid," *International Journal of Nanomedicine*, p. 1713, 2013.
- [35] K. Dziendzikowska, J. Gromadzka-Ostrowska, A. Lankoff, M. Oczkowski, A. Krawczyńska, J. Chwastowska, M. Sadowska-Bratek, E. Chajduk, M. Wojewódzka, M. Dušinská, and M. Kruszewski, "Time-dependent biodistribution and excretion of silver nanoparticles in male Wistar Rats," *Journal of Applied Toxicology*, vol. 32, no. 11, pp. 920–928, 2012.
- [36] J. Pani, "Small Size Nanosilver Multi Organ Toxicity: A Higher Dose Negative Response in In-Vivo and In-Vitro Experimental Application", *Biomedical Journal of Scientific & Technical Research*, vol. 1, no. 4, 2017.
- [37] T. A. Abdulkareem and A. M. Rabee, "Toxicokinetics of Titanium Dioxide (Tio2) Nanoparticles After Intraperitoneal Injection in Male Mice", *eijs*, vol. 61, no. 7, pp. 1555-1564, Jul. 2020.
- [38] S. Razooki and A. Rabee, "Kinetic profile of silver and zinc oxide nanoparticles by intraperitoneal injection in mice, a comparative study", *Periodicals of Engineering and Natural Sciences* (PEN), vol. 7, no. 3, p. 1499, 2019.
- [39] Q. He, Z. Zhang, F. Gao, Y. Li and J. Shi, "In vivo Biodistribution and Urinary Excretion of Mesoporous Silica Nanoparticles: Effects of Particle Size and PEGylation", *Small*, vol. 7, no. 2, pp. 271-280, 2010.